Effect of Somatostatin on Abnormal Growth Hormone and Prolactin Secretion in Patients With the Carcinoid Syndrome

Gómez-Pan, A.; Scanlon, M. F.; Thorner, Michael O.; Rees, Lesley; Hall, R.; Besser, G. M.

doi:10.1111/j.1365-2265.1979.tb02117.x

Cited by 14 publications

(3 citation statements)

References 31 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, however, results on the effect of SRIF on Prl release are conflicting (Carr et al 1975;Gomez-Pan et al 1979;Siler et al 1974) and it is still not clear whether endogenous SRIF may participate in the regulation of Prl secretion (Besser et al 1974;Copinschi et al 1976;Vale et al 1974;Yen et al 1974;Rodriguez-Arnao et al 1981). At present, however, results on the effect of SRIF on Prl release are conflicting (Carr et al 1975;Gomez-Pan et al 1979;Siler et al 1974) and it is still not clear whether endogenous SRIF may participate in the regulation of Prl secretion (Besser et al 1974;Copinschi et al 1976;Vale et al 1974;Yen et al 1974;Rodriguez-Arnao et al 1981).…”

Section: Discussionmentioning

confidence: 99%

Effect of somatostatin on growth hormone and prolactin response to dermorphin in man

Uberti¹,

Trasforini²,

Salvadori

et al. 1985

Acta Endocrinologica

View full text Add to dashboard Cite

The effects of iv somatostatin (somatotrophin release inhibiting factor (SRIF)) on growth hormone (GH) and prolactin (Prl) response to dermorphin (D) were tested in 6 healthy men. In all subjects D induced a significant increase in GH and Prl levels, as expected. SRIF completely blocked the GH-releasing activity of D, whereas it only reduced the Prl-releasing activity.The results confirm that D is a potent stimulant for GH and Prl release in man, and furthermore demonstrate that the action of D on GH secretion can be completely overridden by SRIF.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of somatostatin on growth hormone and prolactin response to dermorphin in man

Uberti¹,

Trasforini²,

Salvadori

et al. 1985

Acta Endocrinologica

View full text Add to dashboard Cite

show abstract

“…In almost half of the cases, elevated levels of other hormones were observed ( Table 3 ). Hyperprolactinemia was the most common symptom associated endocrinopathy which was documented in 44 patients (34.7%) and though usually asymptomatic, it manifested with amenorrhea-galactorrhea syndrome in some patients ( 36 , 55 – 62 ). Prolactin hypersecretion derived rather from GHRH-induced pituitary hyperplasia or stalk compression than from the ectopic tumor itself, as its expression was documented immunohistochemically only in intracranial tumor cases.…”

Section: Methodsmentioning

confidence: 99%

“…Elevated prolactin levels occur more often in patients with acromegaly caused by an ectopic GHRH source than in those with pituitary acromegaly ( 30 ). Less common manifestations included diabetes insipidus ( 63 ), Zollinger-Ellison syndrome ( 49 , 51 ), Cushing syndrome ( 37 , 59 , 64 ), carcinoid syndrome ( 55 ), and typical pheochromocytoma symptoms ( 34 ), as appropriate for corresponding tumors. MEN 1 syndrome was highly probable in 23 patients based on clinical features.…”

Section: Methodsmentioning

confidence: 99%

Acromegaly Caused by Ectopic Growth Hormone Releasing Hormone Secretion: A Review

et al. 2022

View full text Add to dashboard Cite

IntroductionEctopic acromegaly is a rare condition caused most frequently by growth hormone releasing hormone (GHRH) secretion from neuroendocrine tumors. The diagnosis is often difficult to establish as its main symptoms do not differ from those of acromegaly of pituitary origin.ObjectivesTo determine most common clinical features and diagnostic challenges in ectopic acromegaly.Patients and MethodsA search for ectopic acromegaly cases available in literature was performed using PubMed, Cochrane, and MEDline database. In this article, 127 cases of ectopic acromegaly described after GHRH isolation in 1982 are comprehensively reviewed, along with a summary of current state of knowledge on its clinical features, diagnostic methods, and treatment modalities. The most important data were compiled and compared in the tables.ResultsNeuroendocrine tumors were confirmed in 119 out of 121 patients with histopathological evaluation, mostly of lung and pancreatic origin. Clinical manifestation comprise symptoms associated with pituitary hyperplasia, such as headache or visual field disturbances, as well as typical signs of acromegaly. Other endocrinopathies may also be present depending on the tumor type. Definitive diagnosis of ectopic acromegaly requires confirmation of GHRH secretion from a tumor using either histopathological methods or GHRH plasma concentration assessment. Hormonal evaluation was available for 84 patients (66%) and histopathological confirmation for 99 cases (78%). Complete tumor resection was the main treatment method for most patients as it is a treatment of choice due to its highest effectiveness. When not feasible, somatostatin receptor ligands (SRL) therapy is the preferred treatment option. Prognosis is relatively favorable for neuroendocrine GHRH-secreting tumors with high survival rate.ConclusionAlthough ectopic acromegaly remains a rare disease, one should be aware of it as a possible differential diagnosis in patients presenting with additional symptoms or those not responding to classic treatment of acromegaly.

show abstract

Acromegaly Related to Tumoral Secretion of Growth Hormone-Releasing Factor

Sassolas¹,

Chatelain

1986

Human Growth Hormone

View full text Add to dashboard Cite

Effect of Somatostatin on Abnormal Growth Hormone and Prolactin Secretion in Patients With the Carcinoid Syndrome

Cited by 14 publications

References 31 publications

Effect of somatostatin on growth hormone and prolactin response to dermorphin in man

Effect of somatostatin on growth hormone and prolactin response to dermorphin in man

Acromegaly Caused by Ectopic Growth Hormone Releasing Hormone Secretion: A Review

Acromegaly Related to Tumoral Secretion of Growth Hormone-Releasing Factor

Contact Info

Product

Resources

About